The overall risk for uveitis significantly increases after 1 year [66], and a strong association is linked to nivolumab, a PD-1 inhibitor [23,67,68], which accounted for 32% of total uveitis cases but is most strongly associated with ipilimumab, a CTLA-4 inhibitor [23]. The gene discussed is CTLA4; the disease is uveitis.